Dancing Out of Step: A Case of Tuberculous Meningitis Disguised as Childhood Chorea
Background: Acute-subacute pediatric movement disorders (MDs) pose a unique dilemma to clinicians. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: J.J. Garcia, C.M. Tecson-Delos Santos Source Type: research
From Writer's Cramp to Blepharoclonus: An Atypical Journey with a Novel KMT2B Variant
We present a case of KMT2B-related dystonia characterized by unusual clinical traits and a novel variant. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: A. Makharia, D. Garg, A. Agarwal, D. Radhakrishnan, A.K. Pandit, A.K. Srivastava Source Type: research
Posterior cortical atrophy with biomarkers of Alzheimer's disease presenting with corticobasal syndrome and Balint syndrome - A case report
Background: Posterior cortical atrophy (PCA) is a rare neurodegenerative disease that primarily affects the occipital and parietal cortex, characterized by deficits in higher-order visual processing. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: K.N.C. Vo, U.N.L. Ha, T.T.H. Dang, T.V. Nguyen, T.N. Tran Source Type: research
Pimavanserin for Psychosis in Parkinson ’s Disease Dementia: Subgroup Analysis of the HARMONY Trial
Background: Pimavanserin is FDA-approved to treat Parkinson ’s disease (PD) psychosis. We analyzed the effect of pimavanserin on psychosis in the PD dementia (PDD) subgroup from the phase 3 HARMONY trial. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: D. Weintraub, A.J. Espay, V.D. Sharma, P.N. Tariot, V. Abler, S. Pathak, S. Stankovic Source Type: research
The efficacy of Safinamide in improving motor symptoms and the quality of life in Korean patients with motor fluctuations
This study was specifically designed to investigate the efficacy of safinamide maintained without escalating the dose of levodopa and dopamine agonist during the treatment period. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: D.-Y. Kwon, J. Baik, E. Oh, S.-M. Cheon, J.W. Cho, Y.H. Sung, J.-S. Kim, H.-W. Shin, J.-M. Kim, M.Y. Park, H.-I. Ma, J.-H. Park, S.-B. Koh, S.-M. Choi, J. Park, P.H. Lee, T.-B. Ahn, S.J. Kim, C.H. Lyoo, H.-W. Lee, J. Kim, KEEP Study Group Source Type: research
Off-the-shelf bioreactor produced, iPSC-derived neural microtissues containing dopaminergic neurons innervate the striatum and normalize behaviour in a Parkinson rat model
Background: A breadth of preclinical studies (Doi et al, 2020; Piao et al, 2021; Hiller et al, 2022, Kirkeby et al, 2023) is now backing the rationale of pluripotent-stem cell (PSC)-derived cell replacement therapies to restore motor function in Parkinsonian patients. The target for replacement is the major dysfunctional cell population in the disease: ventral mesencephalic A9 dopaminergic neurons, which are particularly vulnerable to the in vitro manipulations required for intracerebral administration (Marchionini et al., 2003). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: N. Prudon, L. Cordero-Espinoza, C. Morel, M. Lepleux, B. Gurchenkov, M. Abarkan, L. Milvoy, P. Morand, F. Moncaubeig, H. Wurtz, L. Poin çot, M. Demarco, A. Jonckeau, J. Plétenka, E. Luquet, M. Lanero Fidalgo, G. Dabee, T. Dufourd, J. Schroeder, K. Aless Source Type: research
Effects of a periodic continuous theta burst stimulation in Parkinson Disease
This study aims to explore the long-term effects of cTBS on improvement of movement symptoms in patients with PD. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: P. Hu, X. Chen, F. Xing, K. Wang Source Type: research
An open-label, randomized, crossover, comparative bioavailability study of Levodopa Cyclops ® and Inbrija® in healthy adult subjects
Background: Many Parkinson ’s disease (PD) patients experience OFF episodes when their disease progresses. OFF episodes are very debilitating and require medication with a predictable and fast onset of effect. This unmet medical need was addressed by apomorphine-based products and Inbrija®, but these products still have li mitations for the patient. Levodopa Cyclops® is a pre-filled, ready-to-use, single-use dry powder inhaler that offers PD patients unrivaled ease-of-use. Previous studies in PD patients have shown Levodopa Cyclops®’ rapid onset of action, ease-of-use during OFF episodes, fast efficacy ( (Source: Pa...
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: M. Hoppentocht, W. Dijkstra, F. Grasmeijer Source Type: research
Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson ’s disease patients with motor fluctuations
Background: Opicapone (OPC), a once-daily catechol-O-methyltransferase inhibitor, was shown to be effective for end-of-dose motor fluctuations in Parkinson ’s disease patients in two large multinational trials (BIPARK-I and II). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: A. Videnovic, W. Poewe, A. Lees, J.J. Ferreira, O. Klepitskaya, R. Loureiro, D. Magalh ães, J. Rocha, P. Soares-da-Silva Source Type: research
Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on Sleep Dysfunction in People With Parkinson's
Background: The study objective was to assess whether 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) improves Parkinson ’s Disease Sleep Scale-2 (PDSS-2) subdomains in people with Parkinson’s (PwP). The PDSS-2 provides a Total Score (TS) and subdomain scores for: Motor Symptoms at Night (MS), Parkinson’s Disease Symptoms at Night (PDS), and Disturbed Sleep (DS). A double-blind 12-week phase 3 trial of LDp/CDp C SCI versus levodopa-carbidopa immediate-release (LD/CD-IR) oral tablets (NCT04380142) suggested improvements in the intention-to-treat (ITT) population PDSS-2 TS. (So...
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: R. Hauser, B. Bergmans, I. Malaty, D. Cobb, J. Homola, L. Bergmann, R. Gupta, J. Jia, M. Shah, K.R. Chaudhuri Source Type: research
Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson's Disease
This study aimed to explore the efficacy of OPC 50 mg versus an extra 100 mg L-dopa dose to treat early wearing-off in Korean patients with PD. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: J.Y. Lee, J.J. Ferreira, H.I. Ma, J.F. Rocha, B. Jeon, on behalf of Korean OGT_001 study investigators Source Type: research
Population pharmacokinetic analysis of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase), in Parkinson ’s Disease patients and healthy volunteers
Background: BIA 28-6156 is an allosteric activator of beta-glucocerebrosidase (GCase) and is being developed by BIAL - Portela& Ca, S.A. as a potential treatment for Parkinson ’s Disease (PD) patients who have PD-risk associated variant in the GBA1 gene (GBA-PD). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: A.A. Ronaghinia, R. Soares, L.M. Magalh ães, D.C. Hilt, J. Holenz Source Type: research
Whole exome sequencing and clinical investigation of young onset dystonia: What can we learn?
In this study, we performed WES in Korean patients with young-onset dystonia to investigate the clinical meaning of WES in dystonia. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: J. Park, J. Youn Source Type: research
Muscle-targeted nutritional support and rehabilitation (MIRT) to treat Parkinsonian patients with risk of fall: A multicentric, randomized, single-blind study
Background: Previous studies have shown how muscle-targeted nutritional support associated with intensive multidisciplinary treatment (MIRT) is able to improve the effects of rehabilitation (1). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: G. Frazzitta, A. Perfetti, P. Marcanti, C. Iarlori, O. Santilli, A. Quaroni, M. Girmegna, A. Molino, C. Bosio, K. Molatore, M. Grancagnolo, M. Ferrario, R. Frappoli, T. Sogoian, J. Mantini, A. Accardo, G. Gabrielli Source Type: research
Comparative profile of neurocognition and quality of life in Parkinson ’s disease with and without psychosis
Background: Deficits in neurocognitive functions have been previously reported in Parkinson ’s disease (PD). Psychosis in PD is one of the most common non-motor symptoms impacting neurocognition and quality of life (QOL). Therefore, it is of paramount importance to gain insight into the ramifications of psychosis for effective treatment and management. Limited research with small samples exists; the current study uniquely examines a larger PD cohort, assessing the difference in cognition and QOL between PD patients with psychosis (PDP) and those without (PDNP). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: T. Baruah, M. Gothwal, S. Bhardwaj, N. Kamble, S. Sundar A, R. Yadav, P.K. Pal, S. Hegde Source Type: research
